What the FDA labels say about taking them together
Golimumab and warfarin
Golimumab's FDA label of September 9, 2025 names warfarin in its drug interactions section; the warfarin label PlainMeds reads does not name golimumab. The golimumab label: “Upon initiation or discontinuation of SIMPONI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration is recommended and the …”
Check it at the source: the golimumab FDA label on DailyMed (effective September 9, 2025, Janssen Biotech, Inc.); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the golimumab label say about warfarin?
Golimumab label, drug interactionsUpon initiation or discontinuation of SIMPONI ARIA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
Source: FDA drug label (Simponi, BLA125289), Janssen Biotech, Inc., effective October 29, 2025 (SPL set f86cb4a7-c358-4136-ae57-b32bda9bba00), via openFDA
Source: FDA drug label (SIMPONI ARIA), Janssen Biotech, Inc., effective September 9, 2025 (SPL set 9e260a47-55af-4c92-8d88-a86ccc767fff), via openFDA; the full label on DailyMed
What does the warfarin label say about golimumab?
Warfarin's label (effective May 29, 2026) does not name golimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Golimumab | Warfarin | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $12,890.32 per mL 50 mg/0.5 mL pen injec | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once